Compare IDEXX Laboratories, Inc. (IDXX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Snap Inc — how do they compare? IDEXX Laboratories, Inc. trades at $567.52 (market cap $44.95B), while Snap Inc trades at $5.3 (market cap $8.79B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.1× Snap Inc's market cap. Which is the better fit depends on your goals.
| IDXX | SNAP | |
|---|---|---|
Market Cap | $44.95B | $8.79B |
Sector | Health | Media |
52-Week High | $766.68 | $9.09 |
52-Week Low | $526.44 | $3.93 |
Enterprise Value | $45.85B | $10.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $566.93, down 3.36% on the day, with a neutral technical signal and strong support near $565. The company reported robust Q2 2026 earnings, beating EPS estimates with $4.27 versus $3.94 expected, and raised full-year EPS guidance to $14.69–14.94. Revenue grew 10% year-over-year, driven by companion animal diagnostics, while profitability remains high with a net margin of 25.03% in 2025. Analyst consensus is bullish with a $683.33 price target, though valuation multiples like P/E of 40.1 suggest a premium.
Outlook is positive due to consistent earnings beats, international expansion, and innovation in veterinary diagnostics, but risks include elevated valuation sensitivity, competitive pressures, and reliance on pet healthcare spending. The stock offers growth potential if execution continues, yet investors should weigh high multiples against sustained profitability trends.
Snap Inc. (SNAP) trades at $5.32, down 3.54% today but showing a bullish technical trend with improving earnings. Q2 2026 revenue grew 19% year-over-year to $1.60 billion, beating expectations, while net loss narrowed by 38% to $164 million. The stock is near its 52-week low of $5.25, with a consensus price target of $7.02 suggesting 32% upside potential. Operating cash flow improved to $656 million in 2025, though net income remains negative at -$460 million.
Outlook: Snap's advertising recovery and cost discipline support a turnaround narrative, but persistent losses and high debt pose risks. Analyst sentiment is mixed with 38% buy ratings. Key catalysts include Q3 earnings and ad revenue trends, while competition and macroeconomic pressures remain headwinds for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
